Asia Fresh News

Asia Fresh Stories

Archive for June 1st, 2012

Lucipark by Lucibel: The New LED for Professionals

leave a comment »

SHENZHEN, China, May 31, 2012 /PRNewswire-Asia/ — Lucibel, a specialist in low-energy lighting, unveils a new LED-based bulb for professional use, perfect for parking structures.

Energy saving LED lamp for parkings and warehouses

Thanks to its protection index (IP) of 65 and its shock-resistance index of 8, the new bulb by Lucibel has been developed especially for heavy-duty working environments, such as parking structures, workshops, and outside work spaces. With a color render index of 85, this LED by Lucibel offers an almost natural lighting effect. Lucipark can be purchased in two color tones: neutral white and bright white.

Reliability, Economy, and Quality

An aluminum heat dissipater guarantees the performance and longevity of the product. Heat quickly flows out of the unit, and along the way, the light’s flux and colorimetry aren’t affected. The perfect balance of quality lighting in the Lucipark bulb prevents any of the blinking or fading often seen in fluorescent products.

The Lucipark bulb consists of 84-140 carefully selected LEDs. Advancing from the traditional lighting powered by fluorescent bulbs, Lucipark allows for up to 50% energy savings. Through the course of its life — 50,000 hours — the bulb considerably reduces energy and maintenance costs.

Ergonomic and Practical Simplicity

Coming pre-wired, the bulb can be put in place using a system of tabs to secure the bulb easily without having to disassemble the fixture, allowing for an easy transition.

The LED technology within each Lucipark guarantees an infinite number of instant light-ups.

Works with dimmer switches and motion/light detectors, therefore allowing the user to customize how the bulb illuminates a selected space. Charles d’HAUSSY, Asia sales Vice-president explains, “Applications for the Lucipark serie are numerous. We delivered projects from Bus station, Sports hall to industrial cold rooms.”

The advantages of Lucipark lighting:

Use in a variety of exterior and industrial settings
Reduction in maintenance costs, thanks to its 50,000-hour lifespan
50%-reduced energy costs over the traditional lighting options
Instant, no-wait light-up
Unlimited number of on/off cycles
Limited environmental impact: less energy, less waste
Specifications:

Comes in 2 formats:
o 60cm — 30W Power

o 120cm — 30W or 50W Power

Comes in two tones (bright white, neutral white)
Available commercially through lighting experts, related distributors, and national installers
Greater Asia distribution hub. Charles d’Haussy (Hong Kong), hk@lucibel.com; Sylar Shi (mainland China), china@lucibel.com
More information available online at: http://www.lucibel.com
About Lucibel

Lucibel is an innovative French company based in France, manufacturing its own products and managing retail for its latest generation lighting solutions using LED technology

For more information, please visit http://www.lucibel.com.

Contacts:

Address: Block A-2F, Tongsheng Technology Building, Longhua Dalang, Shenzhen, China
Phone: +86-0755-2949-1299
Fax: +86-0755-2949-1233
Email: china@lucibel.com

Address: 30, avenue Edouard Belin 92500 RUEIL-MALMAISON, Paris, France
Phone: +33-1-8004-1230
Fax: +33-1-4749-0845
Email: contact@lucibel.com

SOURCE Lucibel

Written by asiafreshnews

June 1, 2012 at 2:22 pm

Posted in Uncategorized

A New Facility for the 10-Year Anniversary of GenScript

leave a comment »

PISCATAWAY, N.J., May 31, 2012 /PRNewswire-Asia/ — GenScript USA Inc., a leading biotech company, has announced the opening of a new R&D facility in Nanjing, China.

This new facility will play a key role in GenScript’s strategy to expand its global business and to reach the emerging market in Asia. GenScript invested $40 million USD to build the new R&D base covering an area of 4,682,700 square feet in JiangNing Science Park. The construction of the new facility broke ground in 2009, and the first phase 765,036 square feet of the R&D base has recently been completed with three 5-story buildings, and two 2-story animal housing buildings with AAALAC and OLAW accredited facilities. New state of the art equipment for gene-synthesis, protein purification and characterization, antibody engineering and drug assays have been installed in the research labs. And the new facilities also offer offices, a meeting center, a cafeteria and an exercise center for employees.

Starting in 2002, GenScript, as a pioneer company, has grown together with the synthetic biology and is the now the world’s largest gene synthesis supplier. With subsidiaries in Europe, Japan, and China, and headquartered in New Jersey, GenScript consistently provides the best research services to the scientific community worldwide. Besides the world-leading gene synthesis service, GenScript offers comprehensive services for biological research and early-phase drug discovery, such as bio-reagents, assay development & screening, antibody drug development, and research animal model services. By developing and applying innovative synthetic biology technologies, GenScript assists researchers in advancing and transforming research in biology.

SOURCE﹛GenScript USA Inc.

Written by asiafreshnews

June 1, 2012 at 12:06 pm

Posted in Uncategorized

Stiefel, a GSK Company, Enters Agreement with Welichem Biotech, Inc. to Acquire a Novel Topical Agent for Psoriasis and Atopic Dermatitis

leave a comment »

RESEARCH TRIANGLE PARK, N.C., May 31, 2012 /PRNewswire-Asia/ — Stiefel, a GSK (NYSE:GSK) company, and Welichem Biotech, Inc. (WBI: CN), have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories outside of mainland China, Taiwan, Macao and Hong Kong. WBI-1001 is currently in Phase II clinical development for the treatment of psoriasis and atopic dermatitis. The transaction is subject to approval by Welichem shareholders.

Welichem will receive an initial payment of CAD$35 million and is eligible to receive additional milestone payments upon achievement of certain clinical development milestones and upon commercialization in certain countries following marketing approval from the corresponding regulatory agencies.

Under terms of the agreement, Stiefel has also received a conditional right to acquire further exclusive rights to develop and commercialize WBI-1001 in mainland China, Taiwan, Macao and Hong Kong, collectively. Upon satisfaction of certain conditions, Welichem will receive an additional payment of CAD$15million.

“I’m delighted to build upon Stiefel’s clinical pipeline of novel dermatology assets with the acquisition of WBI-1001,” said Barbara White, Senior Vice President and Head of Research and Development, Stiefel. “We have a strong commitment to patients with skin conditions and are excited to undertake development of this innovative agent.”

About WBI-1001: WBI-1001 is a novel, non-steroidal, topical anti-inflammatory new chemical entity (NCE) that has demonstrated efficacy and safety in Ph1 and Ph2 clinical trials for the treatment of mild to moderate psoriasis[i] and moderate to severe atopic dermatitis[ii] for up to 12 weeks as a single therapy.

About Stiefel, a GSK company

Stiefel, a GSK company, is committed to advancing dermatology and skin science around the world in order to help people better achieve healthier skin. Stiefel’s dedication to innovation, along with its focus on pharmaceutical, over-the-counter and aesthetic dermatology products, has established Stiefel as a world leader in the skin health industry. To learn more about Stiefel, visit http://www.stiefel.com.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Stiefel, a GSK company, cautions investors that any forward-looking statements or projections made by Stiefel, a GSK company, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect Stiefel, a GSK company’s operations are described under ‘Financial review & risk section” in GSK’s Annual Report 2011 included as exhibit 15.2 to GSK’s Annual Report on Form 20-F for 2011.

References: [i] British Journal of Dermatology; 166(4):853-60 [ii] Journal of the European Academy of Dermatology and Venereology,Early View, Article first published online: 12 NOV 2011

SOURCE﹛Stiefel, a GSK company

Written by asiafreshnews

June 1, 2012 at 11:36 am

Posted in Uncategorized